265,189 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 265,189 shares of the biopharmaceutical company’s stock, valued at approximately $11,156,000.

Other hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $43,000. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $42,000. Wilmington Savings Fund Society FSB purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $83,000. Nomura Asset Management Co. Ltd. purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $93,000. Finally, Van ECK Associates Corp raised its holdings in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 273 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the transaction, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This represents a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,990 shares of company stock valued at $1,037,092. Company insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, January 13th. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Wells Fargo & Company boosted their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, Wedbush reiterated a “neutral” rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $93.50.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $41.26 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The firm has a fifty day moving average price of $42.91 and a 200-day moving average price of $49.10. The company has a market cap of $3.82 billion, a price-to-earnings ratio of -6.51 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.